# Glancy Prongay Wolke & Rotter Investigates NVE Corporation After 30.62% Stock Drop > NVE Corporation stock fell 30.62% after fiscal 2027 second-quarter revenue dropped 47%, prompting a Glancy Prongay Wolke & Rotter securities fraud investigation. - Published: 2026-10-22T18:59:39+00:00 - Section: Legal & Disputes - Author: News Desk - URL: https://newsforagent.com/news/2026-10-22/nve-corporation-glancy-securities-investigation - Source: [Business Wire](https://www.businesswire.com/news/home/20261022854703/en/) ## Key takeaways - NVE Corporation stock fell $31.56 per share, or 30.62%, during intraday trading on October 22, 2026. - NVE reported a 47% quarter-over-quarter revenue decline for the second quarter of fiscal 2027 on October 21, 2026. - Glancy Prongay Wolke & Rotter LLP is investigating whether NVE or its executives made false or misleading statements to investors. Glancy Prongay Wolke & Rotter LLP announced a securities fraud investigation into [NVE Corporation](https://akta.pro/company-profiles/002au8o/nve-corporation) on October 22, 2026, after the company's stock fell $31.56 per share, or 30.62%, during intraday trading. The investigation follows NVE's October 21, 2026 disclosure of second-quarter fiscal 2027 results, [Business Wire](https://www.businesswire.com/news/home/20261022854703/en/) reported. ## NVE's Second-Quarter Results and the Glancy Investigation NVE Corporation is a NASDAQ-listed designer and manufacturer of spintronic GMR and TMR magnetic sensors, IsoLoop digital isolators, and power ICs, serving industrial, medical, automotive, communications, and defense customers from Eden Prairie, Minnesota. On October 21, 2026, NVE reported that quarter-over-quarter revenue decreased 47%, product sales decreased 48%, gross profit decreased 49%, and diluted EPS decreased 51%. During the company's earnings call, Principal Financial Officer Daniel Nelson said the decrease in product sales was due to a short-term inventory adjustment at one of its large medical device customers and a 95% decrease in defense product sales. Nelson said the company expects revenues in the second half of the fiscal year to be consistent with the first half. CEO Peter Eames said the variability was primarily from orders being pulled into quarter 1 from quarter 2. "NVE Corporation stock fell 30.62% following the October 21, 2026 disclosure that NVE reported that second-quarter fiscal 2027 revenue fell 47% quarter over quarter, with product sales down 48%, gross profit down 49% and diluted EPS down 51%," said Charles H. Linehan, Partner at [Glancy Prongay Wolke & Rotter LLP](https://akta.pro/company-profiles/0002nf2/glancy-prongay-wolke-rotter-llp). "Investors who lost money deserve to know whether they were given the full picture, and our investigation will examine that question." Glancy is reviewing whether NVE or its executives may have made false or misleading statements to investors in violation of federal securities laws. The firm announced an investigation into Perimeter Solutions, Inc. for potential breaches of fiduciary duties by its board on October 16, 2026, according to Business Wire Blog. ## NVE's Revenue and Leadership Records According to [akta.pro company records](https://akta.pro/company-data), NVE reported fiscal 2026 total revenue of $26.3 million, with product sales of $25.2 million, and fiscal 2026 net income of $15.2 million at a 57.8% net margin. The company's market capitalization was $533 million as of fiscal 2026, trading at approximately 35x P/E ratio. NVE extended its supplier partnership agreement with Abbott Laboratories for two years through December 2027, with one single customer representing 37% of total revenues. Daniel A. Baker, Ph.D., retired as president and CEO on August 6, 2026, after 25 years leading NVE, and transitioned to chairman. ## NVE's Path to the October Disclosure NVE scheduled its second-quarter results call for October 21, 2026, after the Nasdaq close, with a conference call at 4:00 p.m. Central Time, Stock Titan reported on October 14, 2026. On October 12, 2026, Seeking Alpha described NVE as a supplier of specialized sensors to medical-device manufacturers, including Abbott Laboratories. On October 10, 2026, American Banking and Market News reported that Impinj was rated more favorably than NVE, with a consensus price target of $183.30 implying 3.34% upside. ## What Comes Next for NVE Investors Glancy is investigating potential claims on behalf of NVE investors. Investors who lost money can contact Glancy about the investigation. If a securities class action is later filed against NVE Corporation, investors may have the opportunity to seek appointment as lead plaintiff. ## Companies in this story - [NVE Corporation company profile](https://akta.pro/company-profiles/002au8o/nve-corporation) · website: https://www.nve.com - [Glancy Prongay Wolke & Rotter LLP company profile](https://akta.pro/company-profiles/0002nf2/glancy-prongay-wolke-rotter-llp) · website: https://www.glancylaw.com --- News for Agent · https://newsforagent.com/llms.txt